Evaluation of expansile nanoparticle tumor localization and efficacy in a cancer stem cell-derived model of pancreatic peritoneal carcinomatosis

Nanomedicine

Volumn 11, Issue 9, 2016, Pages 1001-1015

  Herrera, Victoria Lm ^a   Colby, Aaron H ^b   Tan, Glaiza Al ^a   Moran, Ann M ^a   O'Brien, Michael J ^a   Colson, Yolonda L ^c   Ruiz Opazo, Nelson ^a   Grinstaff, Mark W ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cancer stem cells; expansile nanoparticle; paclitaxel; pancreatic carcinomatosis; tumor localization

Indexed keywords

EXPANSILE NANOPARTICLE; NANOPARTICLE; PACLITAXEL; RHODAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CARCINOMATOUS PERITONITIS; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR LOCALIZATION; XENOGRAFT; ANIMAL; CARCINOMA; CHEMISTRY; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; HUMAN; PANCREATIC NEOPLASMS; PATHOLOGY; PERITONEUM;

ANIMALS; CARCINOMA; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASTIC STEM CELLS; PACLITAXEL; PANCREATIC NEOPLASMS; PERITONEUM; RATS; RHODAMINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84965124606     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm-2015-0023     Document Type: Article

References (45)

1. Thomassen I, Lemmens VE, Nienhuijs SW, Luyer MD, Klaver YL, De Hingh IH. Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: A population-based study. Pancreas 42(1), 72-75 (2013).
2. Gottlieb S. Resectable pancreatic cancer needs surgery, then chemotherapy. BMJ 20, 661 (2004).
3. Saif MW. Controversies in the adjuvant treatment of pancreatic adenocarcinoma. J. Pancreas 8, 542-552 (2007).
4. Warshaw AL, Fernandez-Del Castillo C. Pancreatic carcinoma. N. Engl. J. Med. 326(7), 455-465 (1992).
5. Lu Z, Wang J, Wientjes MG, Au JL. Intraperitoneal therapy for peritoneal cancer. Future Oncol. 6(10), 1625-1641 (2010).
6. Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev. 31(1-2), 397-414 (2012).
7. Pancreatic cancer treatment-for health professionals (PDQ®). www.cancer.gov
8. Vogel I, Kruger U, Marxsen J et al. Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: A new prognostic factor. Clin. Cancer. Res. 5(3), 593-599 (1999).
9. Jayne D. Molecular biology of peritoneal carcinomatosis. Cancer Treat. Res. 134 21-33 (2007).
10. Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, Crossley B. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res. 44(8), 3584-3592 (1984).
11. Hermann PC, Huber SL, Herrler T et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3), 313-323 (2007).
12. Penchev VR, Rasheed ZA, Maitra A, Matsui W. Heterogeneity and targeting of pancreatic cancer stem cells. Clin. Cancer. Res. 18(16), 4277-4284 (2012).
13. Innocenti F, Danesi R, Di Paolo A et al. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Drug Metab. Dispos. 23(7), 713-717 (1995).
14. Tsai M, Lu Z, Wang J, Yeh T-K, Wientjes M, Au J. Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel. Pharm. Res. 24(9), 1691-1701 (2007).
15. Colby A, Liu R, Schulz M, Padera R, Colson Y, Grinstaff M. Two-step delivery: exploiting the partition coefficient concept to increase intratumoral paclitaxel concentrations in vivo using responsive nanoparticles. Sci. Rep. 6, 18720 (2015).
16. Colson YL, Liu R, Southard EB et al. the performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis. Biomaterials 32, 832-840 (2011).
17. Gilmore MD, Schulz MM, Liu MR et al. Cytoreductive surgery and intraoperative administration of paclitaxelloaded expansile nanoparticles delay tumor recurrence in ovarian carcinoma. Ann. Surg. Oncol. 20(5), 1684-1693 (2013).
18. Colson YL, Grinstaff MW. Biologically responsive polymeric nanoparticles for drug delivery. Adv. Mater. 24, 3787-3886 (2012).
19. Abouzeid AH, Torchilin VP. the role of cell cycle in the efficiency and activity of cancer nanomedicines. Expert Opin. Drug Deliv. 10(6), 775-786 (2013).
20. Heidel JD, Davis ME. Clinical developments in nanotechnology for cancer therapy. Pharm. Res. 28(2), 187-199 (2011).
21. Jolck RI, Feldborg LN, Andersen S, Moghimi SM, Andresen TL. Engineering liposomes and nanoparticles for biological targeting. Adv. Biochem. Eng. Biotechnol. 125, 251-280 (2011).
22. Langer R. Biomaterials and biotechnology: from the discovery of the first angiogenesis inhibitors to the development of controlled drug delivery systems and the foundation of tissue engineering. J. Biomed. Mater. Res. A 101(9), 2449-2455 (2013).
23. Traitel T, Goldbart R, Kost J. Smart polymers for responsive drug-delivery systems. J. Biomater. Sci. Polym. Ed. 19(6), 755-767 (2008).
24. Wang J, Byrne JD, Napier ME, Desimone JM. More effective nanomedicines through particle design. Small 7(14), 1919-1931 (2011).
25. Day CP, Merlino G, Van Dyke T. Preclinical mouse cancer models: A maze of opportunities and challenges. Cell 163(1), 39-53 (2015).
26. Ijichi H. Genetically-engineered mouse models for pancreatic cancer: advances and current limitations. World J. Clin. Oncol. 2(5), 195-202 (2011).
27. Lonardo E, Hermann PC, Heeschen C. Pancreatic cancer stem cells-update and future perspectives. Mol. Oncol. 4(5), 431-442 (2010).
28. Herrera VL, Decano JL, Tan GA et al. DEspR roles in tumor vasculo-angiogenesis, invasiveness, CSC-survival and anoikis resistance: A 'common receptor coordinator' paradigm. PLoS ONE 9(1), e85821 (2014).
29. Colby AH, Colson YL, Grinstaff MW. Microscopy and tunable resistive pulse sensing characterization of the swelling of pH-responsive, polymeric expansile nanoparticles. Nanoscale 5(8), 3496-3504 (2013).
30. Griset AP, Walpole J, Liu R, Gaffey A, Colson YL, Grinstaff MW. Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. J. Am. Chem. Soc. 131, 2469-2471 (2009).
31. Zubris KA, Liu R, Colby A, Schulz MD, Colson YL, Grinstaff MW. In vitro activity of paclitaxel-loaded polymeric expansile nanoparticles in breast cancer cells. Biomacromolecules 14(6), 2074-2082 (2013).
32. Lei H, Hofferberth SC, Liu R et al. Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids. J. Thorac. Cardiovasc. Surg. 149(5), 1417-1425 (2015).
33. Bertolini G, D'amico L, Moro M et al. Microenvironmentmodulated metastatic CD133+/CXCR4+/EpCAM-lung cancer-initiating cells sustain tumor dissemination and correlate with poor prognosis. Cancer Res. 75(17), 3636-3649 (2015).
34. Zhang SS, Han ZP, Jing YY et al. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med. 10, 85 (2012).
35. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31(13), 3657-3666 (2010).
36. Fröhlich E. the role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomed. 7 5577-5591 (2012).
37. Ferrari R, Lupi M, Colombo C, Morbidelli M, D'incalci M, Moscatelli D. Investigation of size, surface charge, PEGylation degree and concentration on the cellular uptake of polymer nanoparticles. Colloids Surf. B. Biointerfaces 123 639-647 (2014).
38. Morachis JM, Mahmoud EA, Almutairi A. Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. Pharmacol. Rev. 64(3), 505-519 (2012).
39. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31(13), 3657-3666 (2010).
40. Stolzoff M, Ekladious I, Colby AH, Colson YL, Porter TM, Grinstaff MW. Synthesis and characterization of hybrid polymer/lipid expansile nanoparticles: imparting surface functionality for targeting and stability. Biomacromolecules 16(7), 1958-1966 (2015).
41. Zubris KaV, Colson YL, Grinstaff MW. Hydrogels as intracellular depots for drug delivery. Mol. Pharmaceut. 9, 196-200 (2012).
42. Liu R, Gilmore DM, Zubris KA et al. Prevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles. Biomaterials 34(7), 1810-1819 (2013).
43. Cruz-Monserrate Z, Roland CL, Deng D et al. Targeting pancreatic ductal adenocarcinoma acidic microenvironment. Sci. Rep. 4, 4410 (2014).
44. Goldstein D, El-Maraghi RH, Hammel P et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a Phase III trial. J. Natl Cancer Inst. 107(2), pii: dju413 (2015) (Epub ahead of print).
45. Tentes AA, Kyziridis D, Kakolyris S et al. Preliminary results of hyperthermic intraperitoneal intraoperative chemotherapy as an adjuvant in resectable pancreatic cancer. Gastroenterol. Res. Pract. 2012, 506571 (2012).